Results 121 to 130 of about 281,370 (287)

Potent and Selective IGF‐IIR‐Recruiting Bifunctional Molecules for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins

Advanced Science, EarlyView.
Lysosome‐targeting chimeras (LYTACs) enable degradation of extracellular and membrane proteins via lysosomal trafficking. We report a novel IGF‐II mutant (Del1–7, Y27L) that selectively engages IGF‐IIR while avoiding IGF‐IR and IR‐A. mutIGF‐II–based LYTACs enhance target internalization and degradation and support a genetically encodable, all‐protein ...
Yuan Zhao, Yaxian Liao, Pengyun Li, Regina Stasser de Gonzalez, Xuankun Chen, Nicholas S. Nieto, Florence M. Brunel, Nick Cox, Joseph Stock, Matthew McHenry, Guangsen Fu, Penghsuan Huang, Wenxin Wu, Deqin Cai, Lingjun Li, Alexander N. Zaykov, Weiping Tang   +16 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer

Advanced Science, EarlyView.
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen, Yi‐Fan Zhou, Xuan Qi, Ya‐Xin Zhao, Tong Fu, Xi Jin, Minhong Shen, Yi‐Zhou Jiang, Zhi‐Ming Shao   +8 more
wiley   +1 more source

Clinical and Therapeutic Factors Vary by Prognosis in Patients with Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer

Cancer Management and Research, 2021
Zhenfeng Huang,1,* Shiyang Jin,1,* Mengyao Zeng,2,* Jing Shu,1 Yang Liu,1 Jinxing Zhang,1 Bingqi Xu,1 Ming Niu,1 Shanshan Sun,1 Abiyasi Nanding,3 Xiaobo Li,3 Ming Shan,4 Guoqiang Zhang4 1Department of Breast Surgery, Harbin Medical University
Huang Z, Jin S, Zeng M, Shu J, Liu Y, Zhang J, Xu B, Niu M, Sun S, Nanding A, Shan M, Li X, Zhang G   +12 more
doaj  

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of TCE‐secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

Advanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang, Yu‐Chuan Lin, Chih‐Ming Pan, Yeh Chen, Ming‐You Shie, Cheng‐Yu Chen, Kai‐Wen Kan, Yi‐Wen Chen, Ming‐Chao Liu, Chung‐Chun Wu, Yu‐Ting Chiang, Huai‐Ping Ho, Chen‐Yu Lin, Pei‐Ying Lin, Yu‐Han Huang, Steffany Rusli, Wan‐Yu Mao, Pei‐Wen Huang, Sin‐Ting Wang, Wan‐Chen Tsai, Ya‐Hsu Chiu, Ting‐Hsun Lin, Wan‐Ling Chiang, Che‐Kai Chang, Zi‐Lun Lai, Mei‐Chih Chen, Shao‐Chih Chiu, Der‐Yang Cho   +27 more
wiley   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Advanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu, Ling Peng, Lu Lu, Huiyi Feng, Yan Zhong, Guisen Tan, Zhicheng Zhang, Liqin Huang, Chao Su, Ying Xue, Shuo Song, Wenxia Fan, Wei Wang, Fan Zou   +24 more
wiley   +1 more source

Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast. [PDF]

, 2019
Rates of positive margins after surgical resection of invasive lobular carcinoma (ILC) are high (ranging from 18 to 60%), yet the efficacy of re-excision lumpReceptor subtypeectomy for clearing positive margins is unknown.
Alvarado, Michael, Esserman, Laura J, Ewing, Cheryl, Fahrner-Scott, Kelly, Mukhtar, Rita A, Piper, Merisa L, Wong, Jasmine   +6 more
core  

Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+ISH+ and HER2 3+ in HER2-Positive Breast Cancer

Cancer Research and Treatment
Dual anti-HER2 drugs has become the standard regimen for neoadjuvant systematic treatment (NST) to HER2-positive breast cancer patients. However, the efficacy varies greatly among patients with different HER2 protein expression levels.A total of 575 HER2-positive breast cancer patients from multiple centers throughout China from 2013 to 2022 were ...
Lingjun, Ma, Ran, Zheng, Lingyun, Xu, Ying, Zhu, Hong, Yin, Xiaoqing, Zhang, Rong, Deng, Jue, Wang, Xiaoming, Zha   +8 more
openaire   +2 more sources

ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion

Advanced Science, EarlyView.
ZBTB21 is a transcription factor that epigenetically suppresses pyroptosis and MHC‐I antigen presentation, enabling tumor immune evasion. Genetic ablation of ZBTB21 activates pyroptotic cell death and enhances antigen presentation, recruiting CD8+ T cells to overcome immune checkpoint blockade resistance.
Lei Zhao, Linlin Sheng, Jianhao Qiu, Junjie Ma, Kai Jin, Binggong Zhao, Tianrun Miao, Jing Chen, Yehong Li, Zhan Zhang, Dongfeng Sun, Yongmeng Li, Hui Tian   +12 more
wiley   +1 more source

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. [PDF]

, 2019
PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Bartlett, C Huang, Castrellon, A, Diéras, V, Ettl, J, Finn, RS, Gauthier, ER, Gelmon, KA, Harbeck, N, Iyer, S, Joy, AA, Lipatov, O, Lu, DR, Mori, A, Rugo, HS, Slamon, DJ   +14 more
core